 Jaguar Health Inc NASDAQ: JAGX shares are trading higher by 10.90 at 0.70 on continued momentum after the company last week announced an agreement granting Quadri Pharmaceuticals for exclusive promotional, commercialization and distribution rights for specified human indications of crofelemer. 